UniProtKB/Swiss-Prot P40855: Variant p.Ala85Val

Peroxisomal biogenesis factor 19
Gene: PEX19
Feedback?

Variant information Variant position:

85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Valine (V) at position 85 (A85V, p.Ala85Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and hydrophobic (V) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in patients with progressive myoclonus epilepsy and dementia; uncertain significance. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs11550119 [ dbSNP | Ensembl ]

Sequence information Variant position:

85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

299 The length of the canonical sequence.
Location on the sequence:

ASQEKFFQELFDSELASQAT A EFEKAMKELAEEEPHLVEQF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ASQEKFFQELFDSELASQAT--------AEFEKAMKELAE--EEPH--LVEQF

Mouse                         ASQEKFFQELFDSELASQAT--------AEFEKAMKELAE-

Rat                           ASQEKFFQELFDSELASQAT--------AEFEKAMKELAE-

Bovine                        ASQEKFFQELFDSELASQAT--------AEFEKAMKELAE-

Caenorhabditis elegans        ASA--------DQEAAQKAA--------KDFQKMLEQMVT-

Slime mold                    NTNVNDMMDIFKKLLGEETLKNLDAGFDKEYNKDINNNSDD

Baker's yeast                 VDLQNEFANLMKNNGNENNVKT------EDFNKLISALEEA

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 296	Peroxisomal biogenesis factor 19
Region	2 – 91	Necessary for PEX19 function on peroxisome biogenesis
Modified residue	66 – 66	Phosphoserine
Alternative sequence	41 – 299	Missing. In isoform 6.

Literature citations
Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.
Courage C.; Oliver K.L.; Park E.J.; Cameron J.M.; Grabinska K.A.; Muona M.; Canafoglia L.; Gambardella A.; Said E.; Afawi Z.; Baykan B.; Brandt C.; di Bonaventura C.; Chew H.B.; Criscuolo C.; Dibbens L.M.; Castellotti B.; Riguzzi P.; Labate A.; Filla A.; Giallonardo A.T.; Berecki G.; Jackson C.B.; Joensuu T.; Damiano J.A.; Kivity S.; Korczyn A.; Palotie A.; Striano P.; Uccellini D.; Giuliano L.; Andermann E.; Scheffer I.E.; Michelucci R.; Bahlo M.; Franceschetti S.; Sessa W.C.; Berkovic S.F.; Lehesjoki A.E.;
Am. J. Hum. Genet. 108:722-738(2021)
Cited for: VARIANT VAL-85;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.